Literature DB >> 22901813

Cancer vulnerabilities unveiled by genomic loss.

Deepak Nijhawan1, Travis I Zack, Yin Ren, Matthew R Strickland, Rebecca Lamothe, Steven E Schumacher, Aviad Tsherniak, Henrike C Besche, Joseph Rosenbluh, Shyemaa Shehata, Glenn S Cowley, Barbara A Weir, Alfred L Goldberg, Jill P Mesirov, David E Root, Sangeeta N Bhatia, Rameen Beroukhim, William C Hahn.   

Abstract

Due to genome instability, most cancers exhibit loss of regions containing tumor suppressor genes and collateral loss of other genes. To identify cancer-specific vulnerabilities that are the result of copy number losses, we performed integrated analyses of genome-wide copy number and RNAi profiles and identified 56 genes for which gene suppression specifically inhibited the proliferation of cells harboring partial copy number loss of that gene. These CYCLOPS (copy number alterations yielding cancer liabilities owing to partial loss) genes are enriched for spliceosome, proteasome, and ribosome components. One CYCLOPS gene, PSMC2, encodes an essential member of the 19S proteasome. Normal cells express excess PSMC2, which resides in a complex with PSMC1, PSMD2, and PSMD5 and acts as a reservoir protecting cells from PSMC2 suppression. Cells harboring partial PSMC2 copy number loss lack this complex and die after PSMC2 suppression. These observations define a distinct class of cancer-specific liabilities resulting from genome instability.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901813      PMCID: PMC3429351          DOI: 10.1016/j.cell.2012.07.023

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  31 in total

1.  Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates.

Authors:  Alexei F Kisselev; Alfred L Goldberg
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

2.  Characterization of the proteasome using native gel electrophoresis.

Authors:  Suzanne Elsasser; Marion Schmidt; Daniel Finley
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

Review 3.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

4.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

5.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

6.  Gene deletion: a new target for cancer chemotherapy.

Authors:  E Frei
Journal:  Lancet       Date:  1993-09-11       Impact factor: 79.321

Review 7.  Making progress through molecular attacks on cancer.

Authors:  C L Sawyers
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2005

8.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Authors:  Carol Aghajanian; Steven Soignet; Don S Dizon; Christine S Pien; Julian Adams; Peter J Elliott; Paul Sabbatini; Vincent Miller; Martee L Hensley; Sandra Pezzulli; Christina Canales; Adil Daud; David R Spriggs
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

9.  A genetically defined model for human ovarian cancer.

Authors:  Jinsong Liu; Gong Yang; Jennifer A Thompson-Lanza; Armand Glassman; Kimberly Hayes; Andrea Patterson; Rebecca T Marquez; Nelly Auersperg; Yinhua Yu; William C Hahn; Gordon B Mills; Robert C Bast
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

10.  BRAF and RAS mutations in human lung cancer and melanoma.

Authors:  Marcia S Brose; Patricia Volpe; Michael Feldman; Madhu Kumar; Irum Rishi; Renee Gerrero; Eugene Einhorn; Meenhard Herlyn; John Minna; Andrew Nicholson; Jack A Roth; Steven M Albelda; Helen Davies; Charles Cox; Graham Brignell; Philip Stephens; P Andrew Futreal; Richard Wooster; Michael R Stratton; Barbara L Weber
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

View more
  119 in total

1.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

2.  Cancer: Exploiting collateral damage.

Authors:  Ben Lehner; Solip Park
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

3.  Cancer: An essential passenger with p53.

Authors:  James E Bradner
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

4.  Prioritizing predictive biomarkers for gene essentiality in cancer cells with mRNA expression data and DNA copy number profile.

Authors:  Yuanfang Guan; Tingyang Li; Hongjiu Zhang; Fan Zhu; Gilbert S Omenn
Journal:  Bioinformatics       Date:  2018-12-01       Impact factor: 6.937

Review 5.  Functional genomics lead to new therapies in follicular lymphoma.

Authors:  Elisa Oricchio; Hans-Guido Wendel
Journal:  Ann N Y Acad Sci       Date:  2013-05-15       Impact factor: 5.691

6.  Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.

Authors:  Alexia T Kedves; Scott Gleim; Xiaoyou Liang; Dennis M Bonal; Frederic Sigoillot; Fred Harbinski; Sneha Sanghavi; Christina Benander; Elizabeth George; Prafulla C Gokhale; Quang-De Nguyen; Paul T Kirschmeier; Robert J Distel; Jeremy Jenkins; Michael S Goldberg; William C Forrester
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

7.  Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer.

Authors:  Stefano Volinia; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

Review 8.  New strategies in prostate cancer: translating genomics into the clinic.

Authors:  Himisha Beltran; Mark A Rubin
Journal:  Clin Cancer Res       Date:  2012-12-17       Impact factor: 12.531

Review 9.  Targeting tumour-supportive cellular machineries in anticancer drug development.

Authors:  Matthias Dobbelstein; Ute Moll
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

Review 10.  Chromothripsis: chromosomes in crisis.

Authors:  Mathew J K Jones; Prasad V Jallepalli
Journal:  Dev Cell       Date:  2012-11-13       Impact factor: 12.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.